Immunotherapy has taken centre stage as a novel cancer treatment approach. A wide variety of promising immunotherapeutic strategies that aim to generate robust and durable tumour-directed immune responses are available. Systemic administration of antibodies that target the co-inhibitory receptors cytotoxic T lymphocyte antigen 4 (CTLA4) or programmed cell death protein 1 (PD1) on T cells -known as immunecheckpoint blockade -has induced a remarkable long-lasting survival benefit in patients with a variety of tumours. However, so far, this benefit has been seen only in a small fraction of treated patients and at the cost of sometimes severe immune-related adverse events [1] [2] [3] [4] . In adoptive T cell therapy, the number of tumour-specific T cells circulating in the patient is increased by systemic infusion of either ex vivo-expanded autologous tumour-infiltrating T cells or T cells engineered to express high-affinity T cell receptors or chimeric antigen receptors. Encouraging results have been reported using this approach to treat various solid cancer types [5] [6] [7] [8] [9] , but clinical efficacy is hampered by a lack of T cell persistence in vivo, poor T cell functionality and insufficient localization of infused lymphocytes at the tumour Compared with systemic immunotherapy approaches, we propose that local immunomodulation provides opportunities for more specific, more effective and less toxic treatment strategies to promote systemic anticancer immunity 18 . Local immunotherapeutic approaches initially focused on reverting the immunosuppressive microenvironment of the tumour (as reviewed elsewhere 19, 20 ) and in the tumour-draining lymph nodes (TDLNs) 18 . Targeting of the TDLNs is of particular interest, as these are the main site involved in the priming and expansion of tumour-reactive T cells but are also directly influenced by the upstream tumour 21 . In this Opinion article, we discuss therapeutic interventions that modulate the immunosuppressive state of the TDLNs and how these local approaches can confer systemic immunity against cancer. Moreover, we detail how carefully designed three-dimensional (3D) scaffolds can be used as synthetic immune niches. We believe that synthetic immune niches can improve the therapeutic benefit of cancer immunotherapy by allowing more precise manipulation of tumour-directed immune responses while simultaneously preventing toxic side effects (FIG. 1) . We discuss how 3D biomaterial-based scaffolds may enforce systemic antitumour immunity through the delivery of ex vivo-differentiated immune cells or through in situ re-programming of host cells, and we illustrate how these novel strategies may contribute to the development of the next generation of cancer immunotherapies.
Modulating natural immune niches
Tumours use a wide variety of mechanisms to escape immune surveillance in a process termed cancer immunoediting 22 . These mechanisms include the production of immunomodulating factors that impair immune cell priming, suppress existing immune responses and recruit suppressive immune cells instead of effector T cells [22] [23] [24] . Lymph drainage of these tumour-derived factors shifts the TDLNs into an immunosuppressive state, which is detrimental for the interaction between DCs loaded with tumour antigen and naive T cells 21 . Therefore, it will negatively affect the ability of DCs to support robust site 10 . A more tolerable strategy to expand the tumour-reactive T cell pool is the use of dendritic cell (DC)-based cancer vaccines 11, 12 or synthetic therapeutic cancer vaccines 13 . Although clinical responses have been observed with these approaches -resulting in Food and Drug Administration approval for the DC vaccine Provenge, by Dendreon, for prostate cancer 14 -achieving durable clinical responses in established cancers remains a challenge. One important factor that underlies the limited efficacy and substantial toxicity of current immunotherapeutic strategies is their systemic delivery. For example, intravenous application of immune-checkpoint inhibitors requires the use of high doses to attain adequate local concentrations, whereas local administration can achieve strong systemic anticancer T cell responses and decreases the risk of treatment-associated toxicity [15] [16] [17] . Systemic infusion of lymphocytes in adoptive T cell therapy hampers their efficient delivery to the tumour site and requires pretreatment with lymphocyte-depleting chemotherapy and high doses of IL-2, which, although imperative for T cell function and survival, are highly toxic 10 .
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Clinical studies have tested the effect of intradermal injection of CpG-containing oligodeoxynucleotides (CpG ODNs, which bind TLR9), alone or together with the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), around the primary tumour excision site in patients with early-stage melanoma 35, 36 . The combination of CpG ODNs and GM-CSF was found to be the most effective approach to activate various DC subsets within the TDLNs, which coincided with an increased frequency of melanomaspecific CTLs and significantly reduced the occurrence of lymph node metastases 36 . Similarly, local peritumoural injection of oncolytic viruses that can infect and kill tumour cells and also produce GM-CSF led to systemic antitumour CTL responses in patients with melanoma 37, 38 . Clinical studies combining local administration of CpG ODNs with radiotherapy also demonstrated the induction of systemic antitumour effects 39, 40 . Furthermore, studies in animal models have shown that slow local release of CTLA4-blocking antibodies [15] [16] [17] or agonistic antibodies against the co-stimulatory receptor CD40 (REFS 41, 42) or other co-receptors 43 drives potent CTL responses and delays tumour growth. Notably, local administration of low doses of antibodies that block immune checkpoints was equally effective as high-dose systemic nanoparticles with functional ligands or tuning their net charge 45 allows for selective targeting of their cargo to the tumour 46 , TDLNs or specific cell populations residing within TDLNs 47, 48 . Alternatively, T cells may be directly activated by artificial antigen-presenting cells (APCs): that is, nanovaccines that mimic the antigenpresenting and T cell-priming functions of DCs by presenting ligands that stimulate T cells 49 . Thus, nanovaccines are especially useful for delivering multiple signals to immune cells in a tightly regulated manner at specific sites.
Although strategies to re-programme immunosuppressed TDLNs may induce systemic immune responses, the continuous immunosuppressive state of the tumour microenvironment and TDLNs may still administration in inducing systemic antitumour immunity and immunological memory. Moreover, local immunotherapy avoids the high serum antibody levels that are associated with systemic delivery, thereby limiting systemic nonspecific T cell activation and inflammation [15] [16] [17] 41, 42 and reducing toxicity.
Rather than by applying immunostimulants that induce broad immune-cell activation, priming of tumour-specific CTLs can be achieved by providing DCs with synthetic tumour antigens, DC-activating adjuvants and pro-inflammatory cytokines (reviewed in REFS 37, 44) . These DC-acting components may be delivered through bolus injection or can be co-presented via solid-phase polymer-based, lipid-based or inorganic nanovaccines. Loading Nature Reviews | Immunology prove to be a barrier to unleashing the full potential of tumour-reactive CTLs, and therefore, investigation of alternative approaches is warranted. The use of biomaterial-based scaffolds to boost the antitumour response is particularly promising, as it not only provides opportunities for sustained delivery of immune modulators or cells at a specific location, with spatiotemporal control, but also accommodates the establishment of a permissive immunogenic microenvironment.
Design of synthetic immune niches
Engineered scaffolds with defined chemical, mechanical and physical properties create new opportunities for local cancer immunotherapy. They form the building blocks of synthetic immune niches, which are 3D biomaterial-based scaffolds that mimic natural lymph nodes and provide a localized, alternative site for immune-cell interaction, expansion and dispersion. These synthetic immune niches can thereby be exploited to modulate the (anticancer) immune response and circumvent immunosuppressed TDLNs. Re-programming the antitumour immune response at an alternative location is reminiscent of the extranodal immune-cell activation that takes place in naturally occurring tertiary lymphoid structures (TLSs) that surround tumours. Notably, a high density of Synthetic immune niches are particularly promising as immunotherapy approaches, as they not only enable local immunomodulation in an immunogenic context but also address the limitations of current cancer immunotherapeutic strategies related to localized cellular delivery and sustained availability of immune stimulants. Another advantage of synthetic immune niches is that through careful design, the release profiles of molecular and cellular cargo can be fine-tuned to have high spatiotemporal resolution
.
Scaffold-based adoptive cell transfer Adoptive transfer of ex vivo-activated blood DCs that have been pulsed with tumour peptides or of expanded tumour-reactive T cells is a promising immunotherapeutic strategy for generating protective antitumour immune responses. However, challenges remain with respect to insufficient tumour localization, impaired cell survival, difficulty in delivering large numbers of cells and toxicity as a result of coadministered drugs 10, 53, 54 . We propose that delivering cells within 3D scaffolds is a powerful tool to localize immune cells to a specific site and provide them with additional cues to improve their survival, activation and proliferation, followed by their continuous release into the environment (FIG. 2) . Initial evidence for the validity of this approach was provided using alginate-based hydrogels that self-gelate in situ for local delivery of ex vivo-activated DCs together with an IL-15 superagonist, with the goal of promoting CD8 + T cell recruitment [55] [56] [57] . Subcutaneous injection of alginate hydrogels restricted the growth of established melanomas owing to local accumulation of a population of tumour-specific CTLs 55, 56 . This strategy proved to be more effective than injection of the DCs and the IL-15 superagonist alone, which highlights the additive value of the 3D scaffold. Moreover, because ex vivo culturing of DCs is a labourious process, the authors delivered alginate hydrogels that contained CpG ODNs and an IL-15 superagonist, without any DCs, to the peritumoural site and observed suppression of tumour growth that was comparable to that induced by DC-containing hydrogels 56 . In other studies, the delivery of DCs via macroporous fibrin gels significantly outperformed the injection of DCs alone with respect to delaying tumour outgrowth in mice 58 . DCs were found to interact with CTLs that infiltrated the scaffolds, which suggests that T cell priming took place within the engineered niche. Interestingly, this approach resulted in peritumoural TLSs correlates with greater infiltration of the tumour by T H 1 cells and CD8 + memory T cells 50 , resulting in a highly favourable prognosis for almost all human cancers that harbour TLSs 51 . The physical space provided by synthetic immune niches is essential for their function. Scaffold porosity ensures the diffusion of nutrients and chemical cues throughout the matrix 52 , which is important for cell survival and regulation. Moreover, the interconnected porous architecture of the material provides space to encapsulate cells to create a depot of expanding immune-cell populations or allows incoming leukocytes to interact in situ with molecular signals that are attached to the scaffold. As such, 3D scaffolds can modulate tumour-directed immune responses in two different manners: either by acting as a delivery vehicle for potent immune cells together with immunomodulatory agents (FIG. 2) or by serving as an engineered microenvironment that creates a depot of activating ligands for incoming immune cells (FIG. 3) . To function as synthetic immune niches, scaffolds must fulfil the following criteria: first, having sufficient structural rigidity to withstand tissue pressure; second, having sufficient porosity to accommodate the influx and efflux of immune cells; and third, providing sufficient spatiotemporal control over signalling cues to modulate immune cell function. systemic antitumour activity, as it provided protection against tumour re-challenge. The delivery of tumour-specific T cells was initially explored using biodegradable polyethylene glycol (PEG)-g-chito sanbased, temperature-sensitive hydrogels that gelate in situ upon injection 59 . Antigen-specific CTLs could readily traffic through the hydrogels without losing their killing capacity. Another study using a different type of chitosan-based, thermosensitive hydrogel found that the mechanical properties, gelation behaviour and porosity of the scaffold are highly important for T cell survival, ensuring cellular proliferation and dispersion. Importantly, gels containing pores of 50-500 μm in diameter optimally facilitated T cell migration towards the tumour and maintained the ability of the T cells to kill tumour cells 60 . Scaffold-based adoptive transfer of T cells was further explored by creating reservoirs of potent tumour-specific CTLs using macroporous alginate scaffolds that were decorated with adhesion peptides 61 . To promote activation and proliferation of encapsulated T cells, microparticles that contained an IL-15 superagonist and were coated with agonist antibodies specific for CD3, CD28 and CD137 were incorporated into the scaffolds. Following transplantation of the scaffolds into different mouse tumour models, the residing and proliferating CTLs maintained a non-exhausted phenotype. This approach successfully prevented tumour outgrowth even when an immunosuppressive tumour microenvironment was present, whereas direct injection of pre-stimulated CTLs without the scaffold provided only a modest survival advantage.
This two-step vaccine could significantly impair tumour growth when used either prophylactically or therapeutically in melanoma mouse models. A more straightforward system was engineered by the Mooney laboratory, which designed a macroporous polylactide-co-glycolide (PLG) matrix 63, 64 . Notably, whereas GM-CSF was released from the scaffold in a sustained manner (to facilitate DC recruitment), CpG ODNs and tumour cell lysate that were immobilized on the matrix provided continuous stimulation of incoming DCs. Implantation of this vaccine carrier induced a profound expansion of antigen-specific CTLs, resulting in a significant delay in tumour growth and in improved survival in melanoma 63, 65 and glioma 64 murine models. This approach proved to be highly flexible, as an array of different chemokines, cytokines and adjuvants can be incorporated 66, 67 . This PLG-based scaffold vaccine is currently being tested in a phase I clinical trial for metastatic melanoma 68 . To overcome the cumbersome implantation of PLG matrices, Mooney and colleagues also explored biodegradable mesoporous silica rods, which spontaneously self-assemble into a 3D scaffold upon subcutaneous injection 69 . Using this approach, they observed effective accumulation of mature APCs in the scaffold, which resulted in the induction of high numbers of CTLs specific for tumour antigens and an effective delay in tumour growth. Pre-formed alginate cryogels are another group of attractive biomaterials. They are injectable because they collapse owing to shear stress during injection but rapidly regain their shape once in the body 70 . The structure, mechanical strength and localization of these cryogels can be more precisely controlled than, for instance, those of in situ gelating systems 71 . Engineered macroporous cryogels containing GM-CSF, CpG ODNs and irradiated tumour cells facilitate the influx of DCs and promote the uptake of tumour antigen in an immunogenic context, resulting in long-term protective antitumour immunity 72 . Combining these delivery systems with molecules that can modulate the immunosuppressive tumour microenvironment may further improve the priming and effector functions of tumour-specific immune cells. Hence, a dextran-based injectable hydrogel was engineered, which slowly releases DC-recruiting CC-chemokine ligand 20 and presents microparticles that contain not only small interfering RNA (siRNA) to inhibit IL-10 production but also lymphoma-derived Together, these studies indicate that using scaffolds as cell delivery vehicles for adoptive cell therapy to expand DCs and CTLs in situ effectively boosts cell persistence and, at the same time, dictates and maintains cell localization. We believe that in situ instruction and training of immune cells, as exemplified above, will greatly improve current protocols for ex vivo immune-cell expansion.
Scaffold-based cancer vaccines
In addition to being useful in creating reservoirs of immune cells within their 3D scaffolds, we strongly believe that synthetic immune niches are excellent vaccine delivery vehicles. These niches guarantee long-term localized availability of multiple immunomodulatory factors in a spatiotemporally controlled manner. Moreover, the supplied matrix can be designed to attract cells in vivo and provide a local space where incoming DCs can take up tumour antigen in a controlled pro-inflammatory environment (FIG. 3) .
Recent evidence indeed demonstrates successful presentation of immunomodulatory molecules at localized sites to which DCs mobilize. Elegant studies have explored the use of a two-step hybrid strategy: first, DCs are recruited to the matrix by engineering monomethoxyPEG (mPEG)-co-polylactic-co-glycolic acid copolymer hydrogels that release GM-CSF 62 , and second, viral and non-viral vectors carrying antigen and adjuvants are injected close to the gel. Importantly, DCs that are recruited towards the scaffold become activated and effectively migrate from the scaffold towards the TDLNs, leading to the production of interferon-γ (IFNγ) by CTLs. plasmid DNA antigens 73, 74 . These multi-component immunomodulating immune niches promoted a T H 1 cell-biased CD4 + T cell response and a strong CTL response, resulting in long-term tumour protection 73, 74 . Taken together, these studies elegantly show that scaffold-based vaccines effectively restricted tumour growth, whereas bolus injection of components without a scaffold appeared to be ineffective [63] [64] [65] 69, 72 . These results clearly demonstrate the potential of using synthetic scaffolds for the in situ modulation of immune responses, resulting in systemic anticancer immunity. More insight into the importance of immune-cell trafficking in and out of 3D scaffolds and of the timing to support the different phases of the immune response, eventually resulting in systemic anticancer immunity.
Several parameters need to be considered to design optimally functioning synthetic immune niches. It is important to first establish the preferred location of synthetic immune niches with respect to the immunological response. Immune responses that are initiated in peritumoural TLSs seem to be associated with strong antitumour immune responses 50, 51 , which suggests that robust immune priming can take place in the vicinity of the tumour, irrespective of the presence of tumour-derived immunosuppressive factors. So far, most preclinical mouse models used in the work discussed here do not take tumour-induced immunosuppression into account, so research using more sophisticated mouse models is needed to examine the influence of tumour-derived immunosuppressive factors on the efficacy of scaffold-based immunotherapy in relation to the site of administration.
Another important strength of re-programming anticancer immune responses using synthetic immune niches is the flexibility of this approach. Many tools are available to incorporate a range of molecular agents and drugs into scaffolds with varying release profiles
. This flexibility might, for example, be exploited when loading scaffolds with ex vivo-expanded CTLs by incorporating cytokines such as IL-2 to promote T cell survival. A further extension of scaffold-based immunotherapy might focus on engineering immune niches that not only improve CTL responses but also simultaneously counteract tumour-induced immunosuppression. For example, the approaches discussed above can be combined with the sustained delivery of antibodies that block immune checkpoints 65, 75 , agonistic antibodies against co-stimulatory receptors [76] [77] [78] , immunostimulatory agents (such as a transforming growth factor-β inhibitor or IFNα) 79, 80 and/or siRNAs [81] [82] [83] that are released from the scaffold or from nanovaccines incorporated into the scaffold. Finally, scaffolds may support lymphoid neogenesis to simulate peritumoural TLSs via the delivery of lymphoid tissue-inducer stromal cells 84, 85 , combinations of chemokines and cytokines 86 or molecular ligands 87 that induce lymphoid tissue formation.
Obviously, the challenge is to make the right choices, as the number of combinations is almost endless. The process starts with choosing which scaffold and sustained presentation of chemokines and immunomodulators is required to optimize these approaches.
Next-generation immunotherapies
The multidisciplinary research discussed above underpins the importance of collaborative efforts between material engineers, chemists and immunologists to fully exploit the currently available and expanding toolbox of 3D bio materialbased scaffolds. Synthetic immune niches will greatly improve current strategies for cancer immunotherapy in many aspects, provided that they consist of the right scaffolding materials and the essential immunostimulatory cues and work in a highly spatiotemporally controlled manner
Box 1 | Tools for engineering synthetic immune niches
Synthetic immune niches are created from natural or synthetic biomaterials such as polymers, lipids or self-assembled structures. Various engineering tools are available to design scaffolds that have defined physical, chemical and spatiotemporal characteristics, which will influence the immunological response that may be expected, as extensively reviewed elsewhere 90, 91 . The choice and formulation of a scaffold will dictate its structural integrity, rigidity, porosity and degradation behaviour. Structural integrity and rigidity are essential to providing structural support to promote cell activation and interaction. Scaffold porosity is important, as it dictates cell influx and efflux and influences the surface area with which cells can interact. Pores ranging from 100 to 500 μm in diameter optimally ensure the diffusion of nutrients and chemical cues throughout the matrix 52 . Scaffolds may be pre-formed and delivered by implantation 58, 61, 63 or formulated such that they are injectable and gelate in situ, for example, in response to temperature 59, 60, 62 or by the addition of crosslinkers [55] [56] [57] . Minimally invasive delivery through injection is highly favourable, although pre-formed scaffolds enable more control over their mechanical structure and localization and prevent leakage of the injected scaffold material into the surrounding environment, as might be the case for in situ gelating systems 71 . Alternatively, pre-formed scaffolds may be designed such that they can be compressed to make them injectable and can then regain their shape after injection 71, 72 . The strategy by which biomolecules such as chemokines, immunostimulatory ligands and antibodies are incorporated within a scaffold is crucial to determining the spatiotemporal release profiles of these agents. The molecular size of a compound will influence its rate of diffusion through the matrix and into the environment. When compounds are incorporated into scaffolds via physical entrapment, the degradation behaviour of the material will further dictate the release of the compounds. Immunomodulators may also be incorporated through non-covalent hydrophobic or ionic interactions, in which case the hydrophobicity and charge of both the scaffold and the biomolecules will affect cargo release. Finally, covalent coupling of biomolecules by, for instance, bio-orthogonal click chemistry enables their long-term availability until the scaffold disintegrates. Because multiple incorporation strategies will often work in a concerted manner to determine the release profile of biomolecules, the strategies used for incorporation of the desired biomolecules should be carefully considered in the early stages of designing immunomodulatory scaffolds and should be experimentally tested to gain spatiotemporal control over the antitumour immune response.
The table shows the various features to consider when designing and implementing immunomodulatory scaffolds.
Characteristics of material formulation
Methods of administration
Biomolecules integrated
Incorporation strategies
to use and how to decorate it, which will largely depend on what the ultimate goal is: expanding immune cells in vivo, stimulating the efflux of immune cells, attracting DCs for vaccination purposes or slowly releasing immune-checkpoint inhibitors, to mention a few. In addition, immobilization strategies are of utmost importance for controlling the temporal release of biomolecules
. Most studies discussed here used slow release of non-covalently attached biomolecules. It would be particularly interesting to compare various incorporation strategies, including covalent coupling of immunomodulators, to study the influence of release profiles and force sensing on immune-cell activation. Covalent binding of biomolecules may improve the sustained availability of immuno modulatory signals and prevent systemic exposure by dictating the localization of the biomolecules 76, 77 , thereby increasing both efficacy and safety. Future development of advanced methods to exert control over immunomodulator incorporation into and (conditional) release from 3D scaffolds at high spatiotemporal resolution may result in specific spacing of biomolecules to ensure optimal signalling. For example, by taking into consideration the complex clustering of immunomodulating molecules at the immunological synapse or by implementing the release of molecules that are covalently linked to scaffolding materials under the influence of light-mediated or proteolytic cleavage. Such approaches are especially interesting when using scaffolds as artificial APCs to directly prime incoming T cells using covalently attached T cell-stimulating ligands. Dissecting the basic mechanisms that underlie the multitude of interactions within the immune system and the interaction of immune cells with their micro environment is critical to advancing the field of scaffold-based cancer immunotherapy and to gaining more control over anticancer immunity. Precise manipulation of the defined properties of synthetic biomaterials can expose these processes, and therefore, synthetic constructs will also need to be used as quantitative tools to study complex immunological processes 88 .
Barriers to clinical translation
To exploit the full potential of engineered synthetic immune niches and to facilitate clinical translation, several challenges will need to be addressed in the coming years. We feel that this novel field can particularly benefit from lessons learned in regenerative at the systemic level while preventing side effects through local administration. We believe that combining these approaches with approaches that counteract tumour-induced immuno suppression is especially promising to support systemic anticancer immunity, which is of particular relevance when treating patients with metastasis.
The main challenges in the coming years include not only optimizing the design and location of 3D biomaterials but also controlling the spatiotemporal distribution of immunomodulating cues, as the timing of signals to steer immune-cell recruitment, activation and proliferation is critical to the immune response. Overcoming these challenges will require the development of methods to release immuno modulators from or activate immunomodulators in scaffolds in a spatiotemporally controlled manner. To facilitate the clinical translation of synthetic immune niches, it is important to consider key design principles with respect to scaffold composition, degradation behaviour and functionalization from the start and to investigate the safety of these approaches in depth. Multidisciplinary efforts by researchers in materials sciences, chemistry and immunology are essential to achieving these goals. medicine with respect to translating biomaterial-based scaffolds into the clinic 89 . One important issue relates to the biocompatibility and degradation behaviour of biomaterial-based scaffolds. Although the likelihood of systemic toxicity is limited because scaffolds are applied locally, confined acute toxicity and inflammation may still arise in response to the biomaterials used in or factors dispersed from the scaffolds. Moreover, chronic inflammation and immune activation may occur, depending on scaffold composition and degradation behaviour. After the first proof-of-principle studies demonstrate efficacy, the long-term safety of different types of scaffolds containing specific combinations of bioactive molecules will have to be carefully examined. Another principal issue is that the efficacy of synthetic immune niches must be confirmed in preclinical mouse tumour models that recapitulate clinically observed tumour-induced tolerance, metastasis and tumour heterogeneity.
Importantly, regulatory and ethical issues need to be addressed early on when developing synthetic immune niches. This process starts with preferentially using good manufacturing practices and clinical-grade materials in formulations that are already approved for clinical use, as it is easier to obtain clinical approval for modifications of existing systems 89 . Clinical translation of complex scaffolds that release multiple biomolecules and/or deliver autologous cells will be especially challenging. We expect that cell-free scaffold-based cancer vaccines, which present well-defined proteins and chemokines to the immune system in situ, will move to the clinic first owing to fewer regulations and relatively simpler application, as illustrated by a current clinical trial of PLG-based cancer vaccines 68 . The translation of functionalized scaffolds incorporating immune cells and/or immuno modulating signals will follow.
Conclusions
In this Opinion article, we propose that biomaterial-based 3D scaffolds hold great promise in overcoming restrictions that are related to the limited efficacy and systemic toxicity associated with current immunotherapeutic strategies for treating cancer. The early work summarized here demonstrates the unprecedented potential of scaffold-based adoptive cell therapy and scaffold-based cancer vaccines to impede tumour growth
